Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$1.16
-AU$0.14(-11.97%)
At close: 4:00 PM EDT
AU$1.16
-AU$0.14(-11.97%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$2.08
Previous CloseN/A
Volume503.64K
Average Volume (3M)175.32K
Market Cap
AU$32.28M
Enterprise ValueAU$12.61
Total Cash (Recent Filing)AU$6.48M
Total Debt (Recent Filing)AU$14.78K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding30,890,978
10 Day Avg. Volume66,258
30 Day Avg. Volume175,323
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.22
Price to Sales (P/S)9.54
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.40M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue acceleration indicates increasing adoption or commercialization progress for OncoSil, although the base is small. Sustaining this trajectory could improve operating leverage and strengthen the company’s ability to fund clinical, regulatory and market-expansion activities.
Low Financial LeverageMinimal debt and very low leverage reduce solvency pressure and leave greater flexibility to finance clinical development and commercialization. This is an important buffer for a young medical-device company while it works toward recurring revenue and break-even operations.
Targeted Oncology DeviceThe device addresses a defined oncology application through targeted brachytherapy, giving the company a focused product strategy. Clinical evidence, regulatory approvals and commercialization in selected markets could support a defensible specialist position if adoption develops.
Bears Say
Persistent UnprofitabilityNegative gross profit, large operating losses and deep net losses show that current revenue is insufficient to cover product and operating costs. Until scale and cost control improve, profitability remains structurally uncertain and financial resources may continue to be consumed.
Ongoing Cash BurnPersistently negative operating and free cash flow indicates the company is funding operations rather than generating internal cash. Deteriorating free cash flow in the latest year increases dependence on external financing and could constrain investment in commercialization.
Potential Shareholder DilutionAlthough leverage is low, fluctuating equity levels alongside ongoing losses point to potential capital raising and dilution risk. If cash burn persists, shareholders may face reduced ownership or financing terms that limit the company’s strategic flexibility.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$32.28M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 176 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Aug 28, 2026. The company reported -AU$0.236 earnings per share for the quarter.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,890,978 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.236 in its last earnings report. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 88%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Technical Analysis
Polynovo
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―